| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 09/12/2006 | US7105160 Antibody-serum protein hybrids |
| 09/12/2006 | US7105159 Purified monoclonal antibody which binds to a fragment of an outer membrane domain of prostate specific membrane antigen, PSM antigen antibodies conjugated to a radioisotope or a toxin;measuring the amount of PSM antigen in a biological sample |
| 09/12/2006 | US7105150 Contacting neural cells with a reagent that recognizes a determinant on a cell surface marker recognized by monoclonal antibody AC133 or 5E12; selecting cells where there is contact between reagent and determinant |
| 09/12/2006 | US7105149 Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma |
| 09/12/2006 | CA2236598C Treatment of cardiomyopathy by removal of autoantibodies |
| 09/08/2006 | WO2006094134A2 Kim-1 antibodies for treatment of th2-mediated conditions |
| 09/08/2006 | WO2006093794A1 Heterodimeric protein binding compositions |
| 09/08/2006 | WO2006093128A1 Anti-megsin monoclonal antibody |
| 09/08/2006 | WO2006093115A1 Assay method for human orotate phosphoribosyltransferase protein |
| 09/08/2006 | WO2006093088A1 Novel polypeptide, polynucleotide encoding the polypeptide and use the polypeptide and polynucleotide |
| 09/08/2006 | WO2006093080A1 PROCESS FOR PRODUCTION OF CHICKEN RECOMBINANT DIVALENT ANTIBODY FROM CHICKEN SINGLE-CHAIN VARIABLE FRAGMENT (scFv) AND ANTIBODY PRODUCED BY THE PROCESS |
| 09/08/2006 | WO2006093071A1 ANTI-IDIOTYPE ANTIBODY HAVING ANTIFUNGAL ACTIVITY ON FUNGUS CARRYING β-GLUCAN SYNTHASE AND UTILIZATION OF THE SAME |
| 09/08/2006 | WO2006092631A2 Methyltransferases and their uses |
| 09/08/2006 | WO2006067402A3 Agents inibiting the cathelin-like protein cap18/ll-37 |
| 09/08/2006 | WO2006064373A3 Methods of purifying immunologlobulins |
| 09/08/2006 | WO2006058890A3 Method of producing antibodies |
| 09/08/2006 | WO2006041866A3 Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes |
| 09/08/2006 | WO2006029224A3 Methods of using death receptor ligands and cd20 antibodies |
| 09/08/2006 | WO2006028936A3 Heteromultimeric molecules |
| 09/08/2006 | WO2005122741A3 Antibodies against west nile virus and therapeutic and prophylactic uses thereof |
| 09/08/2006 | WO2005091805A3 Methods and compositions for inhibition of metastasis |
| 09/08/2006 | WO2005089372A3 Therapeutic synergy of anti-cancer compounds |
| 09/08/2006 | WO2005059515A3 Method for treating neurological disorders |
| 09/08/2006 | WO2005051307A3 Epha2 agonistic monoclonal antibodies and methods of use thereof |
| 09/08/2006 | WO2005051299A3 Metalloproteinase-binding proteins |
| 09/08/2006 | WO2004028346A3 Detection methods |
| 09/08/2006 | WO2003062385A3 Secretory molecules |
| 09/08/2006 | CA2603677A1 Methyltransferases and their uses |
| 09/08/2006 | CA2599967A1 Kim-1 antibodies for treatment of th2-mediated conditions |
| 09/08/2006 | CA2599669A1 Assay method for human orotate phosphoribosyltransferase protein |
| 09/08/2006 | CA2599265A1 Heterodimeric protein binding compositions |
| 09/08/2006 | CA2597097A1 Treatment of bone disorders |
| 09/08/2006 | CA2573392A1 Methods of detecting a phenotype of a polymorphic protein |
| 09/07/2006 | US20060199948 Of a solution containing an antibody which is present as an aggregate without dissociating into monomers during the chromatography; adding arginine or derivative to a developing solvent utilized during chromatography during elution; quantitative analysis |
| 09/07/2006 | US20060199234 Method of diagnosing wood decay and decay diagnostic agent |
| 09/07/2006 | US20060199223 Chemiluminescent compounds and their use |
| 09/07/2006 | US20060199195 Nucleic acid encoding Schwannomin-Binding-Proteins and products related thereto |
| 09/07/2006 | US20060199176 Coronavirus S peptides |
| 09/07/2006 | US20060198849 Preparation method of igy for preventing and cure mouth disease and the toothpaste base on the igy |
| 09/07/2006 | US20060198848 Administering intravenously a composition comprising monomeric IgA, dimeric IgA, and IgG prepared from pooled human plasma, wherein monomeric and dimeric IgA comprise at least 35% to 55% of total immunoglobulins present in composition |
| 09/07/2006 | US20060198847 Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis |
| 09/07/2006 | US20060198845 Monoclonal antibody against human hepatoma and use thereof |
| 09/07/2006 | US20060198843 a cancer which expresses epidermal growth factor receptor; blocking ligand activation of a receptor; binding of monoclonal antibody 2C4 to ErbB2; chemotherapeutic agents are 5-fluorouracil leucovorin, levamisole |
| 09/07/2006 | US20060198842 treating skeletal muscle atrophy with a corticotropin releasing factor 2 receptor (CRF2R) agonist such as Sauvagine, urocortin II or an antibody |
| 09/07/2006 | US20060198840 increased in vivo half-lives due to the presence of an immunoglobulin G (IgG) constant domain; pharmacokinetics; diagnosis or immunotherapy; antibody conjugates; palivizumab |
| 09/07/2006 | US20060198831 Nitrosylation of protein SH groups and amino acid residues as a therapeutic modality |
| 09/07/2006 | US20060198820 Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| 09/07/2006 | US20060198784 Methods of treatment using antibodies to Neutrokine-alpha |
| 09/07/2006 | DE112004001863T5 Verfahren und Verwendung von Bindungskomponenten zur Verbesserung der Testspezifität The method and use of binding components to improve the specificity test |
| 09/07/2006 | DE10015906B4 Gerichteter Gentransfer in Thy-1-positive Zellen Targeted gene transfer in Thy-1-positive cells |
| 09/06/2006 | EP1698901A1 Method for detecting N-terminal proBNP |
| 09/06/2006 | EP1698899A1 Diagnostic for uterine gland cancer and method of detecting gland cancer cell |
| 09/06/2006 | EP1698698A1 Cell expansion lethal toxin and detection of bacterium belonging to campylobacter genus that targets the same |
| 09/06/2006 | EP1698697A2 SSD-containing protein, process for producing the same and use thereof |
| 09/06/2006 | EP1698694A1 Method of obtaining gene tag |
| 09/06/2006 | EP1698640A1 Method of stabilizing antibody and stabilized solution-type antibody preparation |
| 09/06/2006 | EP1697751A2 Assay and treatment |
| 09/06/2006 | EP1697748A2 Methods for generating multimeric molecules |
| 09/06/2006 | EP1697746A2 Risk markers for cardiovascular disease |
| 09/06/2006 | EP1697741A2 Methods of generating variant proteins with increased host string content and compositions thereof |
| 09/06/2006 | EP1697543A2 Asymmetrically branched polymer conjugates and microarray assays |
| 09/06/2006 | EP1697520A2 Fc polypeptides with novel fc ligand binding sites |
| 09/06/2006 | EP1697516A2 Maize metallothionein promoter |
| 09/06/2006 | EP1697497A2 Liver cancer biomarkers |
| 09/06/2006 | EP1697421A2 Bispecific antibodies |
| 09/06/2006 | EP1697420A2 Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| 09/06/2006 | EP1697419A2 Detection of cd20 in transplant rejection |
| 09/06/2006 | EP1697418A2 Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation |
| 09/06/2006 | EP1697417A2 Antibodies against secretory leukocyte protease inhibitor |
| 09/06/2006 | EP1697416A1 Purification of immunoglobulins |
| 09/06/2006 | EP1697415A1 NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| 09/06/2006 | EP1697413A2 Human lxr alpha variants |
| 09/06/2006 | EP1697410A1 Isolated cytotoxic factor associated with multiple sclerosis and method of detecting said cytotoxic factor |
| 09/06/2006 | EP1697405A1 Lsa-5 liver stage and blood stage antigen of plasmodium falciparum, immunogenic composition comprising said antigen, and vaccines against malaria |
| 09/06/2006 | EP1697403A2 Haemophilus influenzae type iv pili |
| 09/06/2006 | EP1697399A2 A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1 |
| 09/06/2006 | EP1696963A2 Compositions and methods for the treatment of tumor of hematopoietic origin |
| 09/06/2006 | EP1696956A2 Anti-cd52 antibody treatment for diabetes |
| 09/06/2006 | EP1696955A2 Detection of cd20 in therapy of autoimmune diseases |
| 09/06/2006 | EP1696952A1 Anti-retroviral agents, compositions, methods and uses |
| 09/06/2006 | EP1696949A2 Vegf receptor antagonists |
| 09/06/2006 | EP1620726A4 Polypeptides related to natriuretic peptides and methods of their identification and use |
| 09/06/2006 | EP1616181A4 Polypeptides related to natriuretic peptides and methods of their identification and use |
| 09/06/2006 | EP1322383B9 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 09/06/2006 | EP1282642B1 Therapeutic pore-forming peptides |
| 09/06/2006 | EP1071449B1 Use of an antagonist antibody to the inflammatory mediator oncostatin m (osm) |
| 09/06/2006 | EP0955366B1 Antigenic protein originating in malassezia |
| 09/06/2006 | EP0789762B1 Methods for the diagnosis of glaucoma |
| 09/06/2006 | EP0760857B9 Receptor for oncostatin m |
| 09/06/2006 | CN1829806A Method for generating high affinity antibodies |
| 09/06/2006 | CN1829742A Aminated complex-type sugar chain derivatives and process for the production thereof |
| 09/06/2006 | CN1829741A Treatment with anti-VEGF antibodies |
| 09/06/2006 | CN1829740A Connective tissue growth factor antibodies |
| 09/06/2006 | CN1829667A Method for the production of porous carbon-based molded bodies, and use thereof as cell culture carrier systems and culture systems |
| 09/06/2006 | CN1829532A Use of myostatin (GDF8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
| 09/06/2006 | CN1829531A Method of inhibiting tumor growth with anti-tissue factor antibodies |
| 09/06/2006 | CN1829530A Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds |
| 09/06/2006 | CN1829529A Lawsonia intracellularis of european origin and vaccines, diagnostic agents and methods of use thereof |
| 09/06/2006 | CN1829526A Soluble CLCA-1 and antagonists to CLCA-1 |
| 09/06/2006 | CN1829525A Immunotherapeutics for biodefense |